Plus de 40 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Transcranial brain stimulation as innovative therapy for chronic pediatric neuropsychiatric disorder – STIPED (STIPED)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
Due to lack of targeted interventions, compliance issues, insufficient effect sizes and a high non-responder rate to currently available interventions, there is an urgent need to develop innovative and new interventions for chronic paediatric neuropsychiatric disorders, such as Attention-Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). Transcranial direct current stimulati ...
Voir le projet
12
Participants partenaires
TERMINÉ
Scaling-up Packages of Interventions for Cardiovascular disease prevention in selected sites in Europe and Sub-Saharan Africa: An implementation research (SPICES Project) (SPICES)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
The overall research objective of the SPICES project is to implement and evaluate a comprehensive CVD prevention and control program in five settings: a rural & semi-urban community in a low-income country (Uganda), middle income (South Africa) and vulnerable groups in three high-income countries (Belgium, France and United Kingdom) as well as to identify and compare the barriers and facilitators ...
Voir le projet
6
Participants partenaires
TERMINÉ
EUROlinkCAT: Establishing a linked European Cohort of Children with Congenital Anomalies (EUROlinkCAT)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
Over 130,000 children born in Europe every year will have a congenital anomaly (CA; birth defect). These CAs, which are often rare diseases, are a major cause of infant mortality, childhood morbidity and long-term disability. EUROCAT is an established European network of population-based registries for the epidemiologic surveillance of CAs. EUROlinkCAT will use the EUROCAT infrastructure to suppor ...
Voir le projet
25
Participants partenaires
TERMINÉ
ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft in long bone nonUNIONs (ORTHOUNION)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
Current orthopaedic treatments permit spontaneous bone regeneration to unite and heal 90% bone injuries. Non-union associates pain and disability, often requiring biological enhancement. Regenerative medicine research suggests to the general public that alternative treatments based on advanced therapy medicinal products (ATMP) are already available. However, early clinical trials only explore its ...
Voir le projet
13
Participants partenaires
TERMINÉ
Penumbral Rescue by Normobaric O=O Administration in Patients With Ischaemic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial (PROOF)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
Ischemic stroke (IS), caused by occlusion of arteries that supply blood to the brain, remains a leading cause of mortality and morbidity in the world. Disruption of blood and oxygen supply to the brain leads to neuronal death in the ischemic core within minutes. The hypoperfused tissue surrounding the ischemic core, the penumbra, is at high risk for infarction over time but still salvageable. Neur ...
Voir le projet
13
Participants partenaires
TERMINÉ
Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections (COMBACTE-MAGNET)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2021,
Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of multidrug resistant (MDR) Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. There is an unmet medical need to prevent P. aeruginosa infection in critically ill patients and to develop new antibiotics for infections caused by Gram-negative bacte ...
Voir le projet
44
Participants partenaires
TERMINÉ
High-density cortical implants for cognitive neuroscience and rehabilitation of speech using brain-computer interfaces. (BrainCom)
Date du début: 1 déc. 2016, Date de fin: 30 nov. 2021,
The goal of BrainCom is to develop a new generation of neuroprosthetic devices for large-scale and high density recording and stimulation of the human cortex, suitable to explore and repair high-level cognitive functions. Since one of the most invalidating neurospychological conditions is arguably the impossibility to communicate with others, BrainCom primarily focuses on the restoration of speech ...
Voir le projet
10
Participants partenaires
TERMINÉ
BIOlogical therapy CYCLEs towards tailored, needs-driven, safer and cost-effective management of Crohn’s disease (BIOCYCLE)
Date du début: 1 avr. 2015, Date de fin: 31 mars 2021,
"The BIOCYCLE Project proposes to test and critically assess the benefits and risks of an innovative regimen for improving the treatment of Crohn’s disease (CD), a chronic immune-mediated inflammatory disease affecting the gastro-intestinal tract of an increasing number of patients. Currently, the combination of anti-TNFα monoclonal antibodies and immunosuppressants used without interruption is th ...
Voir le projet
13
Participants partenaires
TERMINÉ
REgenerative therapy of intervertebral disc: a double blind phase 2b trial of intradiscal injection of mesenchymal stromal cells in degenerative disc disease of the lomber SPINE unresponsive to conventional therapy (RESPINE)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,
...s. In addition, MRI T2 relaxation measurements demonstrated a significant improvement. To develop the world’s first rigorously proven, effective treatment of DDD, RESPINE aims to assess, via a multicentre, randomized, controlled, phase 2b clinical trial including 112 patients with DDD, the efficacy of an allogenic intervertebral mesenchymal stem cell (MSC)-based therapy. This innovative therapy ai ...
Voir le projet
18
Participants partenaires
TERMINÉ
Children’s Liver Tumour European Research Network (ChiLTERN)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
Liver cancer in the paediatric population is rare with an incidence approximately 1-1.5 per million population. The commonest tumour seen in the childhood population is hepatoblastoma (HB), usually seen in young children and infants. Much rarer (about 10% of paediatric liver cancers) is hepatocellular carcinoma (HCC), usually seen in the teenage population and sometimes associated with underlying ...
Voir le projet
21
Participants partenaires
TERMINÉ
European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates (EHVA)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
...scientists and clinicians; b) the most innovative technologies to profile immune response and virus reservoir; c) the access to large cohort studies bringing together top European clinical scientists/centres in the fields of prophylactic and therapeutic vaccines, d) the access to a panel of experimental HIV vaccines under clinical development that will be used as benchmark, and e) the liaison to a ...
Voir le projet
43
Participants partenaires
TERMINÉ
REgenerative Stem cell therapy for STroke in Europe (RESSTORE)
Date du début: 1 sept. 2015, Date de fin: 31 août 2020,
...g preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke recovery and patients quality of life. RESSTORE European multicentre randomised phase IIb will explore, for the first time, the efficacy (functional recovery) and safety of intravenous infusion of allogenic adipose tissue derived mesenchymal stem cells (ADMSCs) ...
Voir le projet
29
Participants partenaires
TERMINÉ
Are HPV vaccines ‘evolution-proof’? Multilevel evolutionary ecology of human oncoviruses (EVOLPROOF)
Date du début: 1 sept. 2015, Date de fin: 31 août 2020,
There is a threat that evolutionary responses can render vaccines ineffective, as illustrated by the emergence of the increasingly virulent Marek Disease Virus strains in poultry following vaccination campaigns. Assessing the ‘evolution-proof’ nature of vaccines targeting human viruses is challenging because it requires an understanding of the epidemiology, the within-host ecology and the evolutio ...
Voir le projet
2
Participants partenaires
TERMINÉ
Professional cross-priming for ovary and prostate cancer (PROCROP)
Date du début: 1 sept. 2015, Date de fin: 31 août 2020,
...rials for two highly prevalent and unsatisfactorily managed malignant conditions. Industrial partnership provides the unique advantage of producing a rigorously standardized product for eventual multicentre trials.
Voir le projet
8
Participants partenaires
TERMINÉ
A multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease (BETA3_LVH)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2020,
Patients with cardiovascular risk factors, e.g. hypertension and obesity are at risk of developing heart failure with preserved ejection fraction (HFpEF), a highly prevalent disease in the elderly, mostly women population. There is currently no specific, defined treatment for HFpEF, beyond control of risk factors. Activation of cardiac and vascular Beta3-adrenergic receptors (B3AR) represents a ne ...
Voir le projet
15
Participants partenaires
TERMINÉ
Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease: a multicentric, parallel-group, placebo-controlled, randomized clinical trial of deferiprone (FAIR-PARK-II)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2020,
... moderate-dose DFP (30 mg/kg/day) slows the progression of handicap in de novo PD patients while not affecting systemic parameters. The 9-month, parallel-group, randomized, placebo-controlled, multicentre trial will be followed by a 1-month wash-out period. The primary efficacy criterion will be the change in motor and non-motor handicap scores on the Total Movement Disorders Society Unified Parki ...
Voir le projet
17
Participants partenaires
TERMINÉ
Localization in biomechanics and mechanobiology of aneurysms: Towards personalized medicine (BIOLOCHANICS)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2020,
Rupture of Aortic Aneurysms (AA), which kills more than 30 000 persons every year in Europe and the USA, is a complex phenomenon that occurs when the wall stress exceeds the local strength of the aorta due to degraded properties of the tissue. The state of the art in AA biomechanics and mechanobiology reveals that major scientific challenges still have to be addressed to permit patient-specific co ...
Voir le projet
3
Participants partenaires
TERMINÉ
Aneurysmal Arterial Mechanics: Into the Structure (AArteMIS)
Date du début: 1 avr. 2015, Date de fin: 31 mars 2020,
The rupture of an Aortic Aneurysm (AA), which is often lethal, is a mechanical phenomenon that occurs when the wall stress state exceeds the local strength of the tissue. Our current understanding of arterial rupture mechanisms is poor, and the physics taking place at the microscopic scale in these collagenous structures remains an open area of research. Understanding, modelling, and quantifying t ...
Voir le projet
4
Participants partenaires
TERMINÉ
European Sepsis Academy: towards new biomarkers to improve sepsis management (ESA -ITN)
Date du début: 1 mars 2016, Date de fin: 29 févr. 2020,
ESA-ITN will break through the state of the art in sepsis diagnostics and will train 15 early-stage researchers (ESRs) to determine the clinical potency of a variety of new complementary sepsis biomarkers. These cover the full range of the antiinflammatory response in sepsis, at genetic, molecular and cellular level. Rapid and practical biomarker diagnostics for sepsis will be developed by buildin ...
Voir le projet
7
Participants partenaires
TERMINÉ
Combatting Bacterial Resistance in Europe - Carbapenem Resistance (COMBACTE-CARE)
Date du début: 1 mars 2015, Date de fin: 28 févr. 2020,
Multi-drug resistant Gram-negative bacteria (MDR-GNB): the ultimate challenge!Antibiotic resistance is a global public health concern recently elevated to the top three threats identified by the WHO, and subject of numerous national and international government activities. Although focused strategies have beneficially influenced infection rates due to methicillin resistant Staphylococcus aureus (M ...
Voir le projet
23
Participants partenaires
TERMINÉ
Accelerating HIV Cure in Europe (EU4HIVCURE)
Date du début: 1 févr. 2016, Date de fin: 31 janv. 2020,
Finding a CURE for 35 Million individuals living with HIV/AIDS is one of the great global health challenges of the 21st century. The major obstacle to HIV eradication is the persistence of latent HIV cellular reservoirs, where the integrated viral genome is transcriptionally silenced but replication-competent and can escape both Anti-Retroviral Therapy and Immune Responses. The development of nove ...
Voir le projet
6
Participants partenaires
TERMINÉ
European Prevention of Alzheimer’s Dementia Consortium (EPAD)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,
Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions. To achieve this, EPAD will also provide the analytical infras ...
Voir le projet
40
Participants partenaires
TERMINÉ
Combatting Bacterial Resistance in Europe (COMBACTE-NET)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2019,
The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are aro ...
Voir le projet
38
Participants partenaires
TERMINÉ
DevelopIng Genetic medicines for Severe Combined Immunodeficiency (SCID) (SCIDNET)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Severe combined immunodeficiency (SCID) is a devastating rare disorder of immune system development. Affected infants are born without functional immune systems and die within the first year of life unless effective treatment is given. Treatment options are limited to allogeneic haematopoietic stem cell transplantation and autologous stem cell gene therapy. Over the last 15 years, gene therapy for ...
Voir le projet
13
Participants partenaires
TERMINÉ
DC-based immunotherapy to treat Malignant Mesothelioma (H2020MM04)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Asbestos is one of the major occupational carcinogens. The European Union has an extensive history of protecting workers and consumers against asbestos and even adopted a resolution 2012/2065(INI) ‘on asbestos related occupational health threats and prospects for abolishing all existing asbestos’ last year. Although asbestos is banned, it is still massively present in the built environment. Millio ...
Voir le projet
8
Participants partenaires
TERMINÉ
Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients (MIROCALS)
Date du début: 1 sept. 2015, Date de fin: 31 août 2019,
Amyotrophic Lateral Sclerosis (ALS) is a fatal degenerative disorder of the brain and spinal cord affecting some 40,000 individuals in Europe, causing 11,000 deaths each year. Our pioneering work on riluzole showed that it is possible to modify ALS progression but all subsequent trials of potential neuroprotective agents have failed. Thus, drug development in ALS, including trial design, patient s ...
Voir le projet
12
Participants partenaires
TERMINÉ
Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies (SPRINTT)
Date du début: 1 juil. 2014, Date de fin: 30 juin 2019,
The current healthcare systems are built around the traditional paradigm of patients suffering from a single acute illness. They are therefore largely unprepared to face the increasing demands for health services arising from the expansion of an older population with specific medical needs related to multiple chronic disorders. As a consequence, the medical conditions of a large and growing seg ...
Voir le projet
27
Participants partenaires
TERMINÉ
Lifecourse biological pathways underlying social differences in healthy ageing (LIFEPATH)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2019,
"The dramatic differentials in healthy ageing, quality of life and life expectancy between individuals of different socioeconomic groups, is a major societal challenge facing Europe. The overarching aim of the LIFEPATH project is to understand the determinants of diverging ageing pathways among individuals belonging to different socio-economic groups. This will be achieved via an original study de ...
Voir le projet
18
Participants partenaires
TERMINÉ
Multidisciplinary Approaches to Translational Research In Conduct Syndromes (MATRICS)
Date du début: 1 mars 2014, Date de fin: 28 févr. 2019,
Conduct Disorder (CD) is the key paediatric disorder characterized by severe aggression. It is heterogeneous, and our understanding of the neurobiology to subtype aggression is limited. MATRICS is a multidisciplinary consortium of academic partners and SMEs that focuses on the subtyping of aggression both within CD and of the broader cross-disorder trait of aggression. MATRICS will test the hypoth ...
Voir le projet
21
Participants partenaires
TERMINÉ
DIabetes REsearCh on patient sTratification (DIRECT)
Date du début: 1 févr. 2012, Date de fin: 31 janv. 2019,
The overarching aims of the DIRECT consortium, consisting of 20 leading academic groups in diabetes and 5 EFPIA companies, are to identify biomarkers that address current bottlenecks in diabetes drug development and to develop a stratified medicines approach to treatment of type 2 diabetes with either existing or novel therapies.There is heterogeneity in who develops diabetes, the rate at which th ...
Voir le projet
27
Participants partenaires
TERMINÉ
THE MILESTONE PROJECT: Managing the Link and Strengthening Transition from Child to Adult Mental Health Care (MILESTONE)
Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,
Transition to adulthood is the period of onset of most of the serious mental disorders that disable or kill in adult life. Current service configuration of distinct Child and Adolescent Mental Health (CAMHS) and Adult Mental Health (AMHS) Services is considered the weakest link where the care pathway should be most robust. Transition-related discontinuity of care is a major socioeconomic and socie ...
Voir le projet
14
Participants partenaires
TERMINÉ
Hyper-emotionality after neurodegenerative loss of inhibition of the amygdala (URBACH-ALZ)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2018,
"I propose to test how hyper-anxiety in Alzheimer's disease (AD) patients is caused by neurodegeneration in the amygdala, our "center of fear", by comparing with a unique group of Urbach Wiethe disease (UWD) patients with bilateral neurodegeneration of the amygdala (BLA) for which I also construct an animal model. UWD is caused by a very rare genetic mutation occurring in only a handful of individ ...
Voir le projet
1
Participant partenaire
TERMINÉ
Self-management interventions and mutual assistance community services, helping patients with dementia and caregivers connect with others for evaluation, support and inspiration to improve the care experience (CAREGIVERSPRO-MMD)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2018,
According to the World Health Organisation (WHO, ADI), 44 million people around the world have some form of dementia, for which there is no effective intervention, to halt or reverse the progressive cognitive impairment. As Europe’s population is ageing, long-term care for elderly citizens will become an increasing cost for society. To manage this transition healthcare policies in the EU and indiv ...
Voir le projet
8
Participants partenaires
TERMINÉ
COMPACT BIOPHOTONIC PLATFORM FOR DRUG ALLERGY DIAGNOSIS (COBIOPHAD)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2018,
Drug hypersensitivity to antibiotics, mainly Beta-lactams (BLCs) affects more than 2.5 million European citizens. Moreover, preventable adverse drug reactions are estimated in additional hospitalization costs of 1750-4500 €/patient. Currently, the allergy diagnosis is mainly based on the information given by invasive, single, and risky in vivo assays. In daily practice, few in vitro diagnostic met ...
Voir le projet
11
Participants partenaires
TERMINÉ
Clinical trial of autologous adipose-derived mesenchymal stromal cells (ASC) in the treatment of mild to moderate osteoarthritis (ADIPOA2)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,
...(ASCs) are attractive for cellular therapy given the abundance of tissue, high frequency of MSCs and minimally invasive harvest procedure. The EU consortium ADIPOA has shown in a ‘first in man’ 2-centre Phase I safety study that intraarticular injection of a single dose of autologous ASCs to the knee (18 patients, 12 month follow-up) was well-tolerated, had no adverse effects, and resulted in an i ...
Voir le projet
20
Participants partenaires
TERMINÉ
TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,
The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Express ...
Voir le projet
49
Participants partenaires
TERMINÉ
Models of Child Health Appraised (MOCHA)
Date du début: 1 juin 2015, Date de fin: 30 nov. 2018,
Children’s health affects the future of Europe – children are citizens, future workers, parents and carers. Children are dependent on society to provide effective health services (UN Convention on the Rights of the Child). Models of child primary health care vary widely across Europe based on two broad alternatives (primary care paediatricians or generic family doctors), and a variety of models of ...
Voir le projet
20
Participants partenaires
TERMINÉ
I-MOVE+ Integrated Monitoring of Vaccines Effects in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly (I-MOVE-plus)
Date du début: 1 mai 2015, Date de fin: 31 oct. 2018,
The I-MOVE+ Consortium includes European Union (EU) Public Health Institutes, SME and Universities. It aims at measuring and comparing the effectiveness (VE) and impact (VI) of influenza and Pneumococcal vaccines and vaccination strategies a in the elderly population in Europe. The goal is to develop a sustainable platform of primary care practices, hospitals and laboratory networks that share val ...
Voir le projet
33
Participants partenaires
TERMINÉ
Title of Proposal: Restoring the immune system homeostasis and organ function in severe community acquired pneumonia- induced sepsis through adipose derived allogeneic stem cells (SEPCELL Proje (SEPCELL)
Date du début: 1 nov. 2015, Date de fin: 31 oct. 2018,
Sepsis is defined as a systemic inflammatory response to infection, while severe sepsis (SS) is a sepsis complicated by acute organ dysfunction. Lung infections, in particular community-acquire pneumonia (CAP), are the leading cause of SS. The pathophysiologic mechanism of CAP-mediated SS is the complete dysregulation of the patient´s immune system. In an initial phase, the systemic hyperactivatio ...
Voir le projet
7
Participants partenaires
TERMINÉ
PanCare Studies in Fertility and Ototoxicity to Improve Quality of Life after Cancer during Childhood, Adolescence and Young Adulthood (PANCARELIFE)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,
Survival rates after childhood cancer now reach nearly 80% in developed European countries as a result of more effective therapies and better supportive care, leading to a steady increase in the number of survivors in the population. However, the treatments that have improved survival are harsh and cause serious side-effects that can greatly impact survivors’ quality of life in the long term. The ...
Voir le projet